CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni Sells 18,360 Shares of Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 18,360 shares of the business’s stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the transaction, the chief executive officer now directly owns 171,613 shares in the company, valued at $9,473,037.60. This represents a 9.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Samarth Kulkarni also recently made the following trade(s):

• On Monday, December 2nd, Samarth Kulkarni sold 15,000 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $55.10, for a total value of $826,500.00.

CRISPR Therapeutics Stock Down 5.0 %

CRSP stock opened at $47.91 on Friday. The firm has a market cap of $4.11 billion, a PE ratio of -10.96 and a beta of 1.67. The business has a 50 day moving average of $42.25 and a 200-day moving average of $46.06. CRISPR Therapeutics AG has a 12-month low of $36.52 and a 12-month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, research analysts expect that CRISPR Therapeutics AG will post -5.03 earnings per share for the current year.

Hedge Funds Weigh In On CRISPR Therapeutics

Several institutional investors have recently modified their holdings of the business. GF Fund Management CO. LTD. bought a new position in shares of CRISPR Therapeutics in the fourth quarter valued at approximately $71,000. Sunbelt Securities Inc. grew its holdings in CRISPR Therapeutics by 108.6% during the fourth quarter. Sunbelt Securities Inc. now owns 6,165 shares of the company’s stock valued at $238,000 after purchasing an additional 3,210 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in CRISPR Therapeutics by 2.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 690,191 shares of the company’s stock valued at $27,166,000 after purchasing an additional 13,865 shares during the period. Woodline Partners LP grew its holdings in CRISPR Therapeutics by 1.6% during the fourth quarter. Woodline Partners LP now owns 101,600 shares of the company’s stock valued at $3,999,000 after purchasing an additional 1,600 shares during the period. Finally, Westwood Holdings Group Inc. grew its holdings in CRISPR Therapeutics by 18.1% during the fourth quarter. Westwood Holdings Group Inc. now owns 53,102 shares of the company’s stock valued at $2,090,000 after purchasing an additional 8,120 shares during the period. 69.20% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Citigroup dropped their price objective on CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating on the stock in a research note on Tuesday. TD Cowen raised CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price target on the stock in a research note on Wednesday, February 12th. HC Wainwright reaffirmed a “buy” rating and set a $65.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Royal Bank of Canada dropped their price target on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating on the stock in a research note on Wednesday, February 12th. Finally, Truist Financial upped their price target on CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat.com, CRISPR Therapeutics has an average rating of “Hold” and an average target price of $74.40.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.